# Vitexin (Apigenin-8-C-glucoside)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/vitexin-apigenin-8-c-glucoside
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Apigenin-8-C-glucoside, 8-C-glucosylapigenin, Vitexin flavone, C₂₁H₂₀O₁₀, Saponaretin

## Overview

Vitexin is a C-glycosylated flavone (apigenin-8-C-glucoside, C₂₁H₂₀O₁₀, MW 432.38 g/mol) that exerts [antioxidant](/ingredients/condition/antioxidant), [anti-inflammatory](/ingredients/condition/inflammation), and anticancer effects by activating Nrf2-mediated antioxidant enzyme expression, inhibiting mTOR/JNK/p38 MAPK signaling, and modulating [mitochondrial](/ingredients/condition/energy) apoptotic pathways. In DPPH radical scavenging assays, vitexin demonstrates an IC₅₀ of approximately 24.2 μM, surpassing the antioxidant potency of ascorbic acid under equivalent assay conditions.

## Health Benefits

- **[Antioxidant Activity](/ingredients/condition/antioxidant)**: Vitexin scavenges free radicals via its 4′-OH, 7-OH, and 5-OH hydroxyl groups, achieving a DPPH IC₅₀ of ~24.2 μM; its stable C-glycosidic bond at C-8 confers superior radical scavenging capacity relative to O-glycoside analogs.
- **Cardioprotection**: In doxorubicin-induced cardiotoxicity rat models, vitexin at 30 mg/kg elevated FOXO3a expression and suppressed oxidative stress, inflammatory cytokine release, and cardiomyocyte apoptosis, suggesting a protective role against chemotherapy-associated cardiac damage.
- **Anti-Cancer Effects**: Vitexin inhibits proliferation of HCT-116 colon cancer cells across a concentration range of 1–300 μM by shifting the Bcl-2/Bax ratio, releasing cytochrome c, activating caspase-3, and arresting the cell cycle at G2/M phase through suppression of CDK1/cyclin B.
- **Neuroprotection**: Vitexin reduces neuronal oxidative stress and inflammation by upregulating SOD, CAT, GPx, and GSH via Nrf2 activation and inhibiting p38 MAPK and JNK signaling pathways implicated in neurodegeneration.
- **[Glucose Metabolism](/ingredients/condition/weight-management) Modulation**: Vitexin inhibits α-glucosidase with an IC₅₀ of ~244 μM and enhances GLUT4 translocation to the plasma membrane, improving cellular glucose uptake and supporting glycemic control in preclinical diabetic models.
- **[Anti-Inflammatory](/ingredients/condition/inflammation) Action**: By inhibiting matrix metalloproteinases (MMPs), NF-κB downstream targets, and PARP activation, and by promoting M1 macrophage polarization over M2 via VDR modulation, vitexin reduces chronic inflammatory signaling across multiple tissue types.
- **Reproductive and Vascular Protection**: In pregnant rat models of pre-eclampsia, vitexin at 45–60 mg/kg significantly decreased soluble Flt-1 (sFlt-1), increased placental growth factor (PlGF), and alleviated oxidative stress through modulation of the HIF-1α/VEGF axis.

## Mechanism of Action

Vitexin activates the Nrf2 transcription factor, driving upregulation of cytoprotective enzymes including superoxide dismutase (SOD), catalase (CAT), [glutathione](/ingredients/condition/detox) peroxidase (GPx), glutathione S-transferase (GST), and heme oxygenase-1 (HO-1), while concurrently reducing malondialdehyde (MDA) and [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) levels. In oncological contexts, vitexin suppresses the EGFR/PI3K/AKT/mTOR signaling axis and activates p53 and PUMA, shifting the Bcl-2/Bax ratio toward pro-apoptotic Bax dominance, triggering cytochrome c release and caspase-3 cleavage for mitochondria-dependent apoptosis, and arresting cell cycle progression at G2/M via CDK1/cyclin B1 downregulation. Metabolically, vitexin activates AMPKα to inhibit mTOR and enhance GLUT4-mediated glucose uptake, and competitively inhibits intestinal α-glucosidase (IC₅₀ ~244 μM), slowing postprandial glucose absorption. Additionally, vitexin disrupts bacterial quorum-sensing networks in pathogens such as Pseudomonas aeruginosa, reducing biofilm formation and virulence factor expression through downregulation of quorum-sensing regulatory genes.

## Clinical Summary

No human clinical trials investigating vitexin as an isolated compound have been identified in the published literature; all outcome data derive from animal or cell-based experimental models. Rat studies of doxorubicin-induced cardiotoxicity at 30 mg/kg showed restoration of FOXO3a signaling and reduction in cardiac oxidative and [inflammatory](/ingredients/condition/inflammation) markers, while pre-eclampsia models at 45–60 mg/kg demonstrated normalization of angiogenic biomarkers sFlt-1 and PlGF. These preclinical findings indicate biological plausibility for [cardiovascular](/ingredients/condition/heart-health), oncological, and metabolic applications, but effect sizes cannot be reliably extrapolated to human populations without Phase I/II dose-escalation and efficacy trials. Clinical confidence in vitexin's therapeutic applications remains low, and regulatory approval for any specific indication has not been established.

## Nutritional Profile

Vitexin is a pure flavonoid compound (C₂₁H₂₀O₁₀, molecular weight 432.38 g/mol) and does not itself constitute a macronutrient source; it contains no protein, fat, or caloric value in the conventional nutritional sense. As a C-glycoside flavone, its structural backbone is apigenin (4′,5,7-trihydroxyflavone) linked to a glucose moiety at C-8 via a direct carbon-carbon bond, which confers resistance to enzymatic hydrolysis in the upper gastrointestinal tract and distinguishes its bioavailability profile from O-glycoside flavonoids. Key phytochemical properties relevant to bioavailability include moderate water solubility (enhanced at physiological pH), susceptibility to gut microbiota-mediated ring cleavage yielding aglycone metabolites, and phase II hepatic conjugation; the presence of free hydroxyl groups at positions 4′, 7, and 5 is directly responsible for its radical-scavenging activity. Plants naturally containing vitexin also supply co-occurring flavonoids such as isovitexin (apigenin-6-C-glucoside), orientin, and luteolin, which may exert additive or synergistic [antioxidant](/ingredients/condition/antioxidant) effects.

## Dosage & Preparation

- **Isolated Powder (Research Grade)**: Typically dissolved in DMSO (solubility ~16.6 mg/mL) or DMF (solubility ~14.3 mg/mL) for in vitro use; not suitable in these solvents for human consumption.
- **Herbal Extract (Standardized)**: Available in nutraceutical products standardized for vitexin content from passionflower or bamboo leaf extract; standardization percentages vary widely (0.5–5%) across commercial products and are not yet regulated.
- **Animal Study Reference Dose**: 30–60 mg/kg body weight in rodent studies; a direct human equivalent dose has not been established and requires allometric scaling validation.
- **Traditional Plant Consumption**: Plants containing vitexin (pigeon peas, wheat grass, bamboo leaf tea) have been consumed as foods or decoctions; vitexin content per serving is not standardized and depends on species, growing conditions, and preparation.
- **Timing**: No clinical data exist to define optimal timing of administration; preclinical evidence does not specify fed vs. fasted state, though gut microbiota appear to influence C-glycoside absorption and should be considered.
- **Bioavailability Note**: C-glycosidic attachment at C-8 enhances metabolic stability compared to O-glycosides; absorption is modulated by intestinal microbiota-mediated hydrolysis and phase II conjugation (glucuronidation, sulfation).

## Safety & Drug Interactions

No formal human safety studies, maximum tolerated dose data, or adverse event profiles for isolated vitexin supplementation have been published; available preclinical data across multiple rodent models suggest low acute toxicity at therapeutic doses (30–60 mg/kg), with protective rather than damaging effects observed in pancreatic, cardiac, hepatic, and neuronal tissues. Vitexin has demonstrated in vitro synergy with doxorubicin in cancer cell lines, raising a theoretical concern that co-administration could alter chemotherapeutic pharmacodynamics in oncology patients, though no adverse interaction data exist in humans. As a flavonoid with potential α-glucosidase inhibitory activity, vitexin may theoretically potentiate the hypoglycemic effects of antidiabetic medications including metformin and sulfonylureas, warranting caution in diabetic patients pending clinical investigation. Pregnancy and lactation safety cannot be assessed from available data; the observation that high-dose vitexin (45–60 mg/kg) modulates angiogenic factors in pregnant rodents (sFlt-1, PlGF, HIF-1α/VEGF) suggests potential vascular activity that could be relevant in human pregnancy, and use in pregnant or lactating individuals should be avoided until controlled human safety data are available.

## Scientific Research

The current body of evidence for vitexin is entirely preclinical, comprising in vitro cell culture studies and animal model experiments; no peer-reviewed human clinical trials with defined sample sizes or statistically validated effect sizes have been published as of the available literature. In vitro studies in HCT-116 colon cancer cells demonstrated dose-dependent antiproliferative activity and G2/M cell cycle arrest across a 1–300 μM concentration range, while DPPH assays established an IC₅₀ of ~24.2 μM for radical scavenging. Rodent studies have employed doses of 30–60 mg/kg body weight to demonstrate cardioprotective, anti-pre-eclamptic, and [neuroprotective effect](/ingredients/condition/cognitive)s, but interspecies dose extrapolation to humans remains unvalidated. The absence of pharmacokinetic data from human subjects, standardized bioavailability studies, and randomized controlled trials significantly limits the translational confidence of current findings.

## Historical & Cultural Context

Vitexin as an isolated compound has no independent history in traditional medicine; however, the plants that contain it — including passionflower (Passiflora incarnata), used in Western herbalism since the 16th century for anxiety and [insomnia](/ingredients/condition/sleep), and pigeon peas (Cajanus cajan), a staple legume in South Asian and African traditional diets — have centuries-long histories of medicinal and nutritional use. In Traditional Chinese Medicine, bamboo leaf preparations have been employed for their heat-clearing and [antioxidant](/ingredients/condition/antioxidant) properties, and the flavonoid content of these leaves (including vitexin) is now understood to contribute to these traditional effects. Wheat grass and its juice have been consumed in various wellness traditions since the mid-20th century, partly for their purported antioxidant capacity, with vitexin being one of the constituent flavonoids responsible. The identification and structural characterization of vitexin as a discrete chemical entity occurred during the advancement of flavonoid chemistry in the 20th century, and it is named after the genus Vitex, plants from which it was among the earliest isolated.

## Synergistic Combinations

Vitexin and isovitexin (apigenin-6-C-glucoside), its structural isomer, share complementary hydroxylation patterns and have demonstrated additive radical-scavenging capacity in polyphenol-rich plant extracts, suggesting that whole-plant preparations containing both compounds may outperform isolated vitexin alone. In oncological research contexts, vitexin has been studied alongside doxorubicin, where it appeared to enhance cytotoxic selectivity toward cancer cells while simultaneously protecting cardiac tissue from doxorubicin-induced oxidative damage via FOXO3a upregulation, representing a potentially meaningful chemo-adjuvant pairing. Co-administration with other Nrf2-activating compounds such as sulforaphane or quercetin may theoretically amplify [antioxidant](/ingredients/condition/antioxidant) enzyme induction (SOD, CAT, HO-1) through convergent pathway activation, though this specific combination has not been empirically validated in controlled studies.

## Frequently Asked Questions

### What is vitexin and what plants does it come from?

Vitexin is a naturally occurring C-glycosylated flavone with the molecular formula C₂₁H₂₀O₁₀ (MW 432.38 g/mol), structurally identified as apigenin with a glucose moiety attached at the C-8 carbon position via a stable carbon-carbon bond. It is found in pigeon peas (Cajanus cajan), bamboo leaves (Phyllostachys species), passionflower (Passiflora incarnata), and wheat grass (Triticum aestivum), among other plant species distributed across tropical, subtropical, and temperate regions globally.

### How does vitexin compare to vitamin C as an antioxidant?

In DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assays, vitexin demonstrates an IC₅₀ of approximately 24.2 μM, which surpasses the antioxidant potency of ascorbic acid (vitamin C) under equivalent assay conditions, making it one of the more potent plant-derived antioxidant flavonoids identified. This superior activity is attributed to vitexin's free hydroxyl groups at positions 4′, 7, and 5 on the flavone backbone, as well as the stability of its C-glycosidic bond, which resists hydrolytic degradation and preserves antioxidant function more effectively than O-glycoside flavonoid analogs.

### What is the mechanism by which vitexin exerts anti-cancer effects?

Vitexin induces apoptosis in cancer cells primarily through the mitochondrial pathway: it shifts the Bcl-2/Bax ratio toward pro-apoptotic Bax, triggers cytochrome c release from mitochondria, and activates caspase-3 cleavage, while also upregulating p53 and PUMA tumor suppressor proteins. Simultaneously, vitexin arrests the cell cycle at G2/M phase by suppressing CDK1/cyclin B1 activity, and inhibits the EGFR/PI3K/AKT/mTOR signaling cascade, which is frequently dysregulated in solid tumors; these effects have been demonstrated in HCT-116 human colon cancer cells at concentrations of 1–300 μM in vitro.

### Are there any human clinical trials supporting vitexin supplementation?

As of the current published literature, no peer-reviewed human clinical trials with defined sample sizes, randomization, or statistically validated efficacy or safety endpoints have been conducted on isolated vitexin as a supplement. All available evidence is preclinical, derived from in vitro cell assays and rodent models using doses of 30–60 mg/kg body weight; while these findings demonstrate biological plausibility across several therapeutic areas, they cannot be directly extrapolated to human dosing or clinical outcomes without Phase I and Phase II human trials.

### Is vitexin safe to take, and does it interact with any medications?

Formal human safety data for vitexin do not yet exist; preclinical rodent studies at 30–60 mg/kg have not reported hepatotoxicity, nephrotoxicity, or other adverse effects, and protective effects on cardiac, pancreatic, and neural tissues have been observed. However, vitexin may theoretically potentiate the glucose-lowering effects of antidiabetic drugs (e.g., metformin, sulfonylureas) due to its α-glucosidase inhibitory activity (IC₅₀ ~244 μM), and its demonstrated synergy with doxorubicin in cancer models warrants caution in oncology patients; individuals on prescription medications should consult a healthcare provider before use.

### What foods naturally contain vitexin, and can dietary sources provide therapeutic amounts?

Vitexin is found in significant concentrations in passionflower (Passiflora edulis), mung beans, and certain varieties of buckwheat and hawthorn. While these foods do contain measurable vitexin levels, achieving the 30 mg/kg doses used in cardioprotection animal studies through diet alone would be impractical for most people, making supplementation the primary route for therapeutic dosing.

### Why is vitexin's C-glycosidic bond structure superior to O-glycoside forms of apigenin?

Vitexin's C-glycosidic bond (glucose attached directly to the C-8 carbon) creates a much more stable molecular structure that resists enzymatic cleavage in the gastrointestinal tract compared to O-glycosides, where the sugar is attached via oxygen linkages. This structural stability results in higher bioavailability and prolonged radical scavenging capacity in the body, making vitexin a more potent and longer-acting antioxidant than loosely-bound apigenin glycosides.

### Which populations might benefit most from vitexin supplementation based on current research?

Individuals at risk for doxorubicin-induced cardiotoxicity (such as cancer patients undergoing chemotherapy), those with oxidative stress-related conditions, and aging populations show the most promising research applications for vitexin supplementation. However, human clinical trials remain limited, so evidence-based recommendations are primarily based on animal and in vitro studies rather than large-scale human investigations.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*